<< Back To Search

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial


Third Opinion Trial Synopsis:
The study is comparing two different medicines, CC-92480 and carfilzomib plus dexamethasone, to see which one works better in treating a type of cancer called RRMM.
*Third Opinion AI Generated Synopsis

Trial Summary
The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Is There Anything Else You Would Like To Share?